Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 856-864

  Addy, Carol ^a   Assaid, Chris ^a   Hreniuk, David ^a   Stroh, Mark ^a   Xu, Yang ^a   Herring, W Joseph ^a   Ellenbogen, Aaron ^b   Jinnah, H A ^c,d   Kirby, Louis ^e,f   Leibowitz, Mark T ^g,h   Stewart, R Malcolm ^i,j   Tarsy, Daniel ^k   Tetrud, James ^l   Stoch, S Aubrey ^a   Gottesdiener, Keith ^a   Wagner, John ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Quest Research Institute   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Pivotal Research Center   (United States)

^f Provista Life Sciences   (United States)

^g CALIFORNIA CLINICAL TRIALS   (United States)

^h CEDRA Clinical Research   (United States)

ⁱ RADIANT RESEARCH   (United States)

^j Texas Health Presbyterian   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l PARKINSON S INSTITUTE   (United States)

more..

Author keywords

Glutamate receptor; NMDA; NR2B; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AKATHISIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COLD CLAMMY SKIN; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ACTIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSESTHESIA; FEMALE; FLUSHING; HEADACHE; HUMAN; LOOSE FECES; MALE; MONOTHERAPY; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE TIGHTNESS; MYOCLONUS; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SPEECH DISORDER; SYSTOLIC BLOOD PRESSURE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 67650478963     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009336735     Document Type: Article

References (20)

1. Samii A., Nutt JG, Ransom BR Parkinson's disease. Lancet. 2004 ; 363: 1783-1793. (Pubitemid 38698383)
2. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996 ; 334: 71-76. (Pubitemid 26017932)
3. Fearnley JM, Lees AJ Aging and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 ; 114: 2283-2301.
4. Rascol O., Brooks DJ, Kordzyn AD, De Deyn PP, Clarke CE, Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 ; 342: 1484-1491. (Pubitemid 30318272)
5. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord. 1992;7:117-124.
6. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2001;8:101-108. (Pubitemid 32728023)
7. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002 ; 58: 19S - 32S.
8. Greenamyre JT, O'Brien CF N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol. 1991 ; 48: 977-981.
9. Rothman SM, Olney JW Excitotoxicity and the NMDA receptor: still lethal after 8 years. Trends Neurosci. 1995 ; 18: 57-58.
10. Hassani OK, Mouroux M., Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 1996 ; 72: 105-115. (Pubitemid 26092990)
11. Steece-Collier K., Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp Neurol. 2000 ; 163: 239-243. (Pubitemid 30314379)
12. Schrag A., Schelosky L., Scholz U., Poewe W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord. 1999 ; 14: 252-255. (Pubitemid 30011842)
13. Simon N., Micallef J., Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/ pharmacodynamic, randomized, double-blind study. Mov Disord. 2005 ; 20: 803-809. (Pubitemid 41227146)
14. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol. 1999 ; 45: 529-535. (Pubitemid 29218147)
15. Fahn S., Elton RL ; VPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information ; 1987: 153-164.
16. Martinez-Martin P., Gil-Nagel A., Morlan Garcia L., et al. Unified Parkinson's Disease Rating Scale: characteristics and structure. Mov Disord. 1994 ; 9: 76-88.
17. Goetz CG, Stebbins GT Assuring interrater reliability for the UPRDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 ; 19: 1453-1456. (Pubitemid 40104053)
18. Metman LV, Myre B., Verwey N., et al. Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: an argument against multiple baseline assessments. Mov Disord. 2004 ; 19: 1079-1084. (Pubitemid 39302844)
19. Eslamboli A. Marmoset monkey models of Parkinson's disease: which model, when and why ? Brain Res Bull. 2005 68: 140-149. (Pubitemid 41698885)
20. Fox SH, Lang AE, Brotchie JM Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTPlesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord. 2006 ; 21: 1578-1594. (Pubitemid 44742184)